Company intelligence / Profile preview
ImaRx Therapeutics, Inc.
Tucson, Arizona, United Statesimarx.com ↗
- Ownership
- Private
- Employees
- ~32
- Development stage
- Other
01
Overview
The company commercialized urokinase, an FDA-approved thrombolytic agent for treating acute massive pulmonary embolism. Their SonoLysis program (MRX-801 microbubbles with ultrasound and tPA) for ischemic stroke reached Phase 1/2 trials (TUCSON trial), but enrollment was stopped in the second cohort due to safety concerns. The first cohort showed promising safety and efficacy trends.
- Therapeutic areas
- PsychiatryOncologyCardiovascular
- Modalities
- Microbubble technologythrombolytics
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Microbix Biosystems
Beyond the preview
Go deeper on ImaRx Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ImaRx Therapeutics, Inc..